vemurafenib
FDA approves Roche skin cancer combination
November 11, 2015Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib
The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …
Roche submits melanoma drug to FDA
December 15, 2014Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib
Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …
Roche skin cancer drug approval ‘imminent’
August 11, 2011Sales and Marketing Roche, melanoma, vemurafenib
Skin cancer treatment Zelboraf looks set to gain FDA approval months ahead of schedule. Roche and Daiichi Sankyo’s drug is …
Roche impresses at ASCO with vemurafenib
June 6, 2011Research and Development, Sales and Marketing ASCO, Roche, skin cancer, vemurafenib
Roche’s vemurafenib has proven one of the stars of the ASCO cancer conference by increasing overall survival in skin cancer …
Roche aims for wholly personalised skin cancer drug
May 12, 2011Sales and Marketing Roche, personalised medicine, skin cancer, vemurafenib
Roche has submitted its key skin cancer drug vemurafenib to European and American regulators for approval. Vemurafenib (formerly RG7204) has …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
